News - Page 126 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

Post published:January 6, 2022
Post category:Press Release

Read more about the article Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies

Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies

Post published:January 6, 2022
Post category:Press Release

Read more about the article Psychedelic Drug Policy Reform in 2021

Psychedelic Drug Policy Reform in 2021

Post published:January 5, 2022
Post category:Analysis

Read more about the article Psychedelics 2021: A Year in Review

Psychedelics 2021: A Year in Review

Post published:January 5, 2022
Post category:Analysis

Read more about the article The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

Post published:January 5, 2022
Post category:Press Release

Read more about the article PharmaTher Announces Publication of Research Data for KETABET™

PharmaTher Announces Publication of Research Data for KETABET™

Post published:January 4, 2022
Post category:Press Release

Read more about the article Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation

Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation

Post published:January 4, 2022
Post category:Press Release

Read more about the article Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders

Post published:January 4, 2022
Post category:Press Release

Read more about the article MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway

MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway

Post published:January 4, 2022
Post category:Press Release

Read more about the article MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

Post published:January 4, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.